Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors – a review of patent literature from 2019–30 June 2023

.

Source: Expert Opinion on Therapeutic Patents - April 5, 2024 Category: Drugs & Pharmacology Authors: Kyle D. ReichlEsther C. Y. LeeAriamala GopalsamyOncology R & D, AstraZeneca, Waltham, MA, USA Source Type: research